Journal
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY
Volume 74, Issue 4, Pages 323-332Publisher
WILEY
DOI: 10.1111/aji.12412
Keywords
Escherichia coli; genital innate immunity; Lactobacillus
Categories
Funding
- National Institute of Allergy and Infectious Diseases, [UM1AI068633, UM1AI068615, UM1AI106707]
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, component of the U.S. National Institutes of Health
- National Institute of Mental Health, component of the U.S. National Institutes of Health
- Public Health Service grant [K23AI089271]
Ask authors/readers for more resources
Introduction Innate activity against Escherichia coli in female genital secretions may represent contributions from vaginal bacteria and host soluble immune mediators. We analyzed the relationship between E. coli inhibitory activity, soluble immune mediators, and vaginal bacteria in participants in MTN-004, a placebo-controlled trial of VivaGel (R), a candidate product for topical HIV pre-exposure prophylaxis. Methods Escherichia coli inhibitory activity was quantified by colony reduction assay. Endocervical concentrations of interleukin (IL)-1 beta, IL-6, IL-12p40, macrophage inflammatory protein (MIP)-1 alpha, granulocyte-macrophage colony-stimulating factor (GM-CSF), lactoferrin, and secretory leukocyte protease inhibitor (SLPI) were quantified to generate a cumulative mediator score. Vaginal bacteria were characterized by quantitative cultures. Results In the two placebo arms, higher soluble immune mediator score was associated with greater E. coli inhibitory activity (beta = 17.49, 95% CI [12.77, 22.21] and beta = 13.28, 95% CI [4.76, 21.80]). However, in the VivaGel arm, higher concentrations of E. coli (beta = -3.80, 95% CI [-6.36, -1.25]) and group B Streptococcus (beta = -3.91, 95% CI [-6.21, -1.60]) were associated with reduced E. coli inhibitory activity. Conclusions Both host mediators and vaginal bacteria impact E. coli inhibition in genital secretions. The relative contributions of host mediators and bacteria varied between women who used VivaGel vs placebos.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available